Hirtle Callaghan & Co’s AbbVie ABBV Stock Holding History

Hirtle Callaghan & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-69	Closed	-$6K	–	46
2019 Q1	$6K	Buy	+69	New	+$5.64K	﹤0.01%	46
2018 Q2	–	Sell	-69	Closed	-$7K	–	107
2018 Q1	$7K	Hold	69	–	–	﹤0.01%	99
2017 Q4	$7K	Buy	+69	New	+$6.5K	﹤0.01%	113
2015 Q1	–	Sell	-22,044	Closed	-$1.44M	–	16
2014 Q4	$1.44M	Sell	22,044 -800	-4%	-$50.4K	0.33%	47
2014 Q3	$1.32M	Sell	22,844 -340	-1%	-$18.9K	0.22%	56
2014 Q2	$1.31M	Hold	23,184	–	–	0.18%	79
2014 Q1	$1.19M	Sell	23,184 -320	-1%	-$16.2K	0.2%	66
2013 Q4	$1.24M	Buy	23,504 +621	+3%	+$30.5K	0.17%	68
2013 Q3	$1.02M	Buy	22,883 +19,601	+597%	+$869K	0.17%	73
2013 Q2	$136K	Buy	+3,282	New	+$144K	1.57%	19

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Hirtle Callaghan & Co's ABBV Position: Q2 2019 in Review

Hirtle Callaghan & Co sold out of AbbVie (ABBV) in Q2 2019, closing a stake of 69 shares — an estimated $6K sold.

Hirtle Callaghan & Co first reported a position in ABBV in Q2 2013 and held it in 10 quarters. The position peaked at $1.44M in Q4 2014. 2,020 funds tracked by Wall St. Rank hold ABBV as of Q2 2019.

Hirtle Callaghan & Co reported no remaining AbbVie position as of Q2 2019 after selling out during the quarter.
Hirtle Callaghan & Co sold 69 AbbVie shares in Q2 2019, an estimated $6K.
Hirtle Callaghan & Co first reported a position in AbbVie in Q2 2013 and held it in 10 quarters.
Hirtle Callaghan & Co's AbbVie position peaked at $1.44M in Q4 2014.
2,020 funds tracked by Wall St. Rank held AbbVie as of Q2 2019.

Based on Hirtle Callaghan & Co's 13F filing for Q2 2019, filed 13 Aug 2019.